Literature DB >> 21802959

Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: the road ahead.

J Carlijn Van Gaal1, Eveline S J M De Bont, Suzanne E J Kaal, Yvonne Versleijen-Jonkers, Winette T A van der Graaf.   

Abstract

Rhabdomyosarcoma (RMS) is a rare type of soft tissue sarcoma that mainly affects children, but also occurs in adolescents and (young) adults (AYA). Despite dramatic survival improvements reported by international study groups in children over the past decades, the awareness of a dismal outcome for older patients with RMS has grown. In contrast to the world-wide organization of care for children with RMS, standard care in adults lags behind. A step forward in RMS management for patients of all ages is urgently needed. Both paediatric oncologists and medical oncologists are essential players in development of a concept of RMS care, but bringing two worlds together seems not so easy. This review provides an overview which highlights the similarities and differences in children and adults with RMS. Furthermore, it comes up with a novel concept to overcome the virtual gap between the treatment approach of children and AYA with RMS.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21802959     DOI: 10.1016/j.critrevonc.2011.06.005

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  12 in total

1.  PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.

Authors:  Sarah N Dumont; Alexander J Lazar; Julia A Bridge; Robert S Benjamin; Jonathan C Trent
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-17       Impact factor: 4.553

2.  Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.

Authors:  Maria Böhm; Marco Wachtel; Joana G Marques; Natalie Streiff; Dominik Laubscher; Paolo Nanni; Kamel Mamchaoui; Raffaella Santoro; Beat W Schäfer
Journal:  J Clin Invest       Date:  2016-10-17       Impact factor: 14.808

Review 3.  Uncovering metabolism in rhabdomyosarcoma.

Authors:  Eugenio Monti; Alessandro Fanzani
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

4.  Embryonal rhabdomyosarcoma of the perineum in an adult: a case report.

Authors:  Sidy Ka; Freddy Gnangnon; Mamadou Moustapha Dieng; Doudou Diouf; Jaafar Thiam; Pape Macoumba Gaye; Ahmadou Dem
Journal:  J Med Case Rep       Date:  2016-12-20

5.  Stage 1 embryonal rhabdomyosarcoma of the female genital tract: a retrospective clinical study of nine cases.

Authors:  Guangwen Yuan; Hongwen Yao; Xiaoguang Li; Hongjun Li; Lingying Wu
Journal:  World J Surg Oncol       Date:  2017-02-07       Impact factor: 2.754

6.  Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.

Authors:  Anke E M van Erp; Melissa H S Hillebrandt-Roeffen; Laurens van Houdt; Emmy D G Fleuren; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

7.  Response to the combination use of pazopanib with olaratumab in a patient with lung-metastatic embryonal rhabdomyosarcoma: a case report.

Authors:  Tuo Xing; Yalei Zhang; Xukai Li; Minzhang Guo; Wenhua Liang; Jianxing He
Journal:  Transl Lung Cancer Res       Date:  2021-01

8.  Rhabdomyosarcoma in Adults: A Retrospective Analysis of Case Records Diagnosed between 1979 and 2018 in Western Denmark.

Authors:  Vivi-Nelli Mäkinen; Akmal Safwat; Ninna Aggerholm-Pedersen
Journal:  Sarcoma       Date:  2021-08-30

Review 9.  Rhabdomyosarcoma in adolescent and young adult patients: current perspectives.

Authors:  Daniela Egas-Bejar; Winston W Huh
Journal:  Adolesc Health Med Ther       Date:  2014-06-17

10.  Pleomorphic rhabdomyosarcoma infiltrating thoracic spine in a 59-year-old female patient: Case report.

Authors:  Matthias Spalteholz; Jens Gulow
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2017-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.